Intervention Review

You have free access to this content

Albendazole for lymphatic filariasis

  1. David Addiss2,
  2. Carrol L Gamble3,
  3. Paul Garner4,
  4. Hellen Gelband5,
  5. Henry OD Ejere6,
  6. Julia A Critchley1,*,
  7. International Filariasis Review Group4

Editorial Group: Cochrane Infectious Diseases Group

Published Online: 21 JAN 2009

Assessed as up-to-date: 13 AUG 2005

DOI: 10.1002/14651858.CD003753.pub3

Database Title

Additional Information

How to Cite

Addiss D, Gamble CL, Garner P, Gelband H, Ejere HOD, Critchley JA, International Filariasis Review Group. Albendazole for lymphatic filariasis. Cochrane Database of Systematic Reviews 2005, Issue 4. Art. No.: CD003753. DOI: 10.1002/14651858.CD003753.pub3.

Author Information

  1. 1

    Newcastle University, Institute of Health and Society, Newcastle, Tyne and Wear, UK

  2. 2

    Centers for Disease Control and Prevention, Division of Parasitic Diseases, Atlanta, Georgia, USA

  3. 3

    University of Liverpool, Centre for Medical Statistics and Health Evaluation, Liverpool, UK

  4. 4

    Liverpool School of Tropical Medicine, International Health Group, Liverpool, Merseyside, UK

  5. 5

    Resources for the Future, Washington, DC, USA

  6. 6

    Metropolitan Hospital, Department of Medicine, New York, USA

*Julia A Critchley, Institute of Health and Society, Newcastle University, William Leech Building, The Medical School, Newcastle, Tyne and Wear, NE2 4HH, UK. J.A.Critchley@newcastle.ac.uk.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 21 JAN 2009

SEARCH

ARTICLE TOOLS

View Full Article (HTML) Summary (60K)Standard (391K)Full (696K)
[Analysis 1.1]
Analysis 1.1. Comparison 1 Albendazole versus placebo, Outcome 1 Microfilariae (mf) prevalence: all participants (both mf positive or negative at baseline).
[Analysis 1.2]
Analysis 1.2. Comparison 1 Albendazole versus placebo, Outcome 2 Microfilariae (mf) prevalence: only participants mf positive at baseline.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Albendazole versus placebo, Outcome 3 Antigen prevalence: all participants (both mf positive or negative at baseline).
[Analysis 1.4]
Analysis 1.4. Comparison 1 Albendazole versus placebo, Outcome 4 New clinical disease.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Albendazole versus placebo, Outcome 5 Pre-existing clinical disease.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Albendazole versus placebo, Outcome 6 Adverse events.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Albendazole versus ivermectin, Outcome 1 Microfilariae (mf) prevalence: all participants (both mf positive or negative at baseline).
[Analysis 2.2]
Analysis 2.2. Comparison 2 Albendazole versus ivermectin, Outcome 2 Microfilariae (mf) prevalence: only participants mf positive at baseline.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Albendazole versus ivermectin, Outcome 3 Antigen prevalence: all participants (antigen positive or negative at baseline).
[Analysis 2.4]
Analysis 2.4. Comparison 2 Albendazole versus ivermectin, Outcome 4 New clinical disease.
[Analysis 2.5]
Analysis 2.5. Comparison 2 Albendazole versus ivermectin, Outcome 5 Pre-existing clinical disease.
[Analysis 2.6]
Analysis 2.6. Comparison 2 Albendazole versus ivermectin, Outcome 6 Adverse events.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Albendazole plus ivermectin versus ivermectin, Outcome 1 Microfilariae (mf) prevalence: all participants (both mf positive or negative at baseline).
[Analysis 3.2]
Analysis 3.2. Comparison 3 Albendazole plus ivermectin versus ivermectin, Outcome 2 Microfilariae (mf) prevalence: only participants mf positive at baseline.
[Analysis 3.3]
Analysis 3.3. Comparison 3 Albendazole plus ivermectin versus ivermectin, Outcome 3 Antigen prevalence: all participants (antigen positive or negative) at baseline.
[Analysis 3.4]
Analysis 3.4. Comparison 3 Albendazole plus ivermectin versus ivermectin, Outcome 4 Antigen prevalence: only participants antigen positive at baseline.
[Analysis 3.5]
Analysis 3.5. Comparison 3 Albendazole plus ivermectin versus ivermectin, Outcome 5 New clinical disease.
[Analysis 3.6]
Analysis 3.6. Comparison 3 Albendazole plus ivermectin versus ivermectin, Outcome 6 Pre-existing clinical disease.
[Analysis 3.7]
Analysis 3.7. Comparison 3 Albendazole plus ivermectin versus ivermectin, Outcome 7 Adverse events.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Albendazole versus diethylcarbamazine (DEC), Outcome 1 Microfiliariae (mf) prevalence: all participants (both mf positive or negative at baseline).
[Analysis 4.2]
Analysis 4.2. Comparison 4 Albendazole versus diethylcarbamazine (DEC), Outcome 2 Microfilariae (mf) prevalence: only participants mf positive at baseline.
[Analysis 4.3]
Analysis 4.3. Comparison 4 Albendazole versus diethylcarbamazine (DEC), Outcome 3 Antigen prevalence: all participants (both antigen positive or negative at baseline).
[Analysis 4.4]
Analysis 4.4. Comparison 4 Albendazole versus diethylcarbamazine (DEC), Outcome 4 Antigen prevalence: only participants antigen positive at baseline.
[Analysis 4.5]
Analysis 4.5. Comparison 4 Albendazole versus diethylcarbamazine (DEC), Outcome 5 Adverse events.
[Analysis 4.6]
Analysis 4.6. Comparison 4 Albendazole versus diethylcarbamazine (DEC), Outcome 6 Adverse events: scrotal syndrome.
[Analysis 5.1]
Analysis 5.1. Comparison 5 Albendazole plus diethylcarbamazine (DEC) versus DEC, Outcome 1 Microfilariae (mf) prevalence: all participants (both mf positive or negative at baseline).
[Analysis 5.2]
Analysis 5.2. Comparison 5 Albendazole plus diethylcarbamazine (DEC) versus DEC, Outcome 2 Microfilariae (mf) prevalence: only participants mf positive at baseline.
[Analysis 5.3]
Analysis 5.3. Comparison 5 Albendazole plus diethylcarbamazine (DEC) versus DEC, Outcome 3 Antigen prevalence: all participants (both antigen positive and negative at baseline).
[Analysis 5.4]
Analysis 5.4. Comparison 5 Albendazole plus diethylcarbamazine (DEC) versus DEC, Outcome 4 Antigen prevalence: only participants antigen positive at baseline.
[Analysis 5.5]
Analysis 5.5. Comparison 5 Albendazole plus diethylcarbamazine (DEC) versus DEC, Outcome 5 Adverse events.
View Full Article (HTML) Summary (60K)Standard (391K)Full (696K)